Search
dexfenfluramine (Redux)
Tradename: Redux. DEA-controlled substance: class 2. DEA-controlled substance: class 4 [3].
FDA approved in 1996.
Withdrawn from US market is 1997 [2].
Indications: obesity
Dosage: 15 mg PO BID with meals
Tabs: 15 mg.
Pharmacokinetics:
1) eliminated by liver
2) 1/2life: 11-30 hours
Adverse effects: pulmonary hypertension (23-46/100,000)
Interactions
drug adverse effects (more general classes)
General
fenfluramine (Pondimin, Ponderil, Ponderex, Adipomin, Fintepla)
Properties
MISC-INFO: elimination route LIVER
1/2life 11-30 HOURS
therapeutic-range 30-300 NG/ML
toxic-range >1000 NG/ML
pregnancy-category C
safety in lactation -
Database Correlations
PUBCHEM correlations
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Fresno Bee, Dec. 2000
- Harrison's Principles of Internal Medicine, 14th ed.
Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 461